Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Trabert, B, Ness, RB, Lo-Ciganic, W-H, Murphy, MA, Goode, EL, Poole, EM, Brinton, LA, Webb, PM, Nagle, CM, Jordan, SJ, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), , Risch, HA, Rossing, MA, Doherty, JA, Goodman, MT, Lurie, G, Kjær, SK, Hogdall, E, Jensen, A, Cramer, DW, Terry, KL, Vitonis, A, Bandera, EV, Olson, S, King, MG, Chandran, U, Anton-Culver, H, Ziogas, A, Menon, U, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Wu, AH, Pearce, CL, Pike, MC, and Berchuck, A et al. "Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium." Journal of the National Cancer Institute 106, no. 2 (February 2014): djt431-.

Full Text

Charbonneau, B, Block, MS, Bamlet, WR, Vierkant, RA, Kalli, KR, Fogarty, Z, Rider, DN, Sellers, TA, Tworoger, SS, Poole, E, Risch, HA, Salvesen, HB, Kiemeney, LA, Baglietto, L, Giles, GG, Severi, G, Trabert, B, Wentzensen, N, Chenevix-Trench, G, for AOCS/ACS group, , Whittemore, AS, Sieh, W, Chang-Claude, J, Bandera, EV, Orlow, I, Terry, K, Goodman, MT, Thompson, PJ, Cook, LS, Rossing, MA, Ness, RB, Narod, SA, Kupryjanczyk, J, Lu, K, Butzow, R, Dörk, T, Pejovic, T, Campbell, I, and Le, ND et al. "Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10." Cancer research 74, no. 3 (February 2014): 852-861.

Full Text

Kokosis, G, Schmitz, R, Secord, AA, Havrilesky, LJ, Berchuck, A, Mantyh, CR, and Erdmann, D. "A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect." Gynakologe 47, no. 10 (January 1, 2014): 784-787.

Full Text

Trabert, B, Ness, RB, Lo-Ciganic, WH, Murphy, MA, Goode, EL, Poole, EM, Brinton, LA, Webb, PM, Nagle, CM, Jordan, SJ, Australian Ovarian Cancer Study Group, ACSOC, Risch, HA, Rossing, MA, Doherty, JA, Goodman, MT, Lurie, G, Kjær, SK, Hogdall, E, Jensen, A, Cramer, DW, Terry, KL, Vitonis, A, Bandera, EV, Olson, S, King, MG, Chandran, U, Anton-Culver, H, Ziogas, A, Menon, U, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Wu, AH, Pearce, CL, Pike, MC, Berchuck, A, Schildkraut, JM, and Wentzensen, N et al. "Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium." Journal of the National Cancer Institute 106, no. 2 (January 1, 2014).

Full Text

Davidson, BA, Rubatt, JM, Corcoran, DL, Teoh, DK, Bernardini, MQ, Grace, LA, Soper, WJ, Berchuck, A, Siamakpour-Reihani, S, Chen, W, Owzar, K, Murphy, SK, and Secord, AA. "Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines." Frontiers in Oncology 4 (January 2014): 163-.

Full Text

Earp, MA, Kelemen, LE, Magliocco, AM, Swenerton, KD, Chenevix-Trench, G, Lu, Y, Hein, A, Ekici, AB, Beckmann, MW, Fasching, PA, Lambrechts, D, Despierre, E, Vergote, I, Lambrechts, S, Doherty, JA, Rossing, MA, Chang-Claude, J, Rudolph, A, Friel, G, Moysich, KB, Odunsi, K, Sucheston-Campbell, L, Lurie, G, Goodman, MT, Carney, ME, Thompson, PJ, Runnebaum, IB, Dürst, M, Hillemanns, P, Dörk, T, Antonenkova, N, Bogdanova, N, Leminen, A, Nevanlinna, H, Pelttari, LM, Butzow, R, Bunker, CH, and Modugno, F et al. "Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA." Human Genetics 133, no. 5 (January 1, 2014): 481-497.

Full Text

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (January 1, 2014): 3651-3659.

Full Text

Pooley, KA, Bojesen, SE, Weischer, M, Nielsen, SF, Thompson, D, Amin Al Olama, A, Michailidou, K, Tyrer, JP, Benlloch, S, Brown, J, Audley, T, Luben, R, Khaw, K-T, Neal, DE, Hamdy, FC, Donovan, JL, Kote-Jarai, Z, Baynes, C, Shah, M, Bolla, MK, Wang, Q, Dennis, J, Dicks, E, Yang, R, Rudolph, A, Schildkraut, J, Chang-Claude, J, Burwinkel, B, Chenevix-Trench, G, Pharoah, PDP, Berchuck, A, Eeles, RA, Easton, DF, Dunning, AM, and Nordestgaard, BG. "A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk." Hum Mol Genet 22, no. 24 (December 15, 2013): 5056-5064.

Full Text

Rodriguez, GC, Barnes, HJ, Anderson, KE, Whitaker, RS, Berchuck, A, Petitte, JN, Lancaster, JM, Wenham, RM, Turbov, JM, Day, R, Maxwell, GL, and Carver, DK. "Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen." Cancer Prev Res (Phila) 6, no. 12 (December 2013): 1283-1292.

Full Text

Johnatty, SE, Beesley, J, Gao, B, Chen, X, Lu, Y, Law, MH, Henderson, MJ, Russell, AJ, Hedditch, EL, Emmanuel, C, Fereday, S, Webb, PM, Australian Ovarian Cancer Study Group, , Goode, EL, Vierkant, RA, Fridley, BL, Cunningham, JM, Fasching, PA, Beckmann, MW, Ekici, AB, Hogdall, E, Kjaer, SK, Jensen, A, Hogdall, C, Brown, R, Paul, J, Lambrechts, S, Despierre, E, Vergote, I, Lester, J, Karlan, BY, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Bean, Y, Pejovic, T, Levine, DA, Goodman, MT, and Camey, ME et al. "ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas." Gynecol Oncol 131, no. 1 (October 2013): 8-14.

Full Text

Pages